BioCentury | Feb 7, 2011
Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
BC Week In Review | Aug 2, 2010
Clinical News

CP404: Phase I data

In a placebo-controlled, U.S. Phase I trial in 12 patients, single doses of 2, 4 and 8 mg intranasal CP404 were well tolerated with no significant adverse events reported. Additionally, the compound demonstrated a trend...
Items per page:
1 - 2 of 2